THE END OF AIDS?

TEST MORE] + [TREAT EARLY] + [STAY SAFE] = ENDING HIV

Everything has changed. We can end HIV.
The treatment target
HIV care cascade – WHO target

Diagnosed: 90%
On treatment: 90%
Virally suppressed: 90%
### ACHIEVING THE 90–90–90 TARGETS,

#### FIGURE 3.2. COUNTRIES THAT HAVE ACHIEVED THE 90–90–90 TARGETS OR ARE NEAR TO ACHIEVING THEM, MOST RECENT COUNTRY DATA

<table>
<thead>
<tr>
<th>Achieved (90% or greater)</th>
<th>Nearly achieved (85–89%)</th>
<th>Nearly achieved (65–72%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FIRST 90</strong></td>
<td><strong>SECOND 90</strong></td>
<td><strong>THIRD 90</strong></td>
</tr>
<tr>
<td>Australia, Belarus</td>
<td>Australia, Algeria</td>
<td>Botswana</td>
</tr>
<tr>
<td>Denmark</td>
<td>Botswana, Comoros</td>
<td>Brazil</td>
</tr>
<tr>
<td>Malaysia</td>
<td>France</td>
<td>Botswana</td>
</tr>
<tr>
<td>Sweden</td>
<td>Haiti</td>
<td>Botswana, Brazil</td>
</tr>
<tr>
<td>Thailand</td>
<td>Ireland</td>
<td>Botswana, Brazil</td>
</tr>
<tr>
<td></td>
<td>Malawi</td>
<td>Botswana, Brazil</td>
</tr>
<tr>
<td></td>
<td>Nepal</td>
<td>Botswana, Brazil</td>
</tr>
<tr>
<td></td>
<td>Nicaragua</td>
<td>Botswana, Brazil</td>
</tr>
<tr>
<td></td>
<td>Nicaragua</td>
<td>Botswana, Brazil</td>
</tr>
<tr>
<td></td>
<td>Rwanda</td>
<td>Botswana, Brazil</td>
</tr>
<tr>
<td></td>
<td>South Africa</td>
<td>Botswana, Brazil</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>Botswana, Brazil</td>
</tr>
</tbody>
</table>

Source: UNAIDS special analysis, 2017; see annex on methods for more details.

1 Data are for 2016, except as follows: 2015: Bulgaria, Germany, Hungary, Netherlands, Sweden, Switzerland, United Kingdom. 2014: Belgium, Canada, Serbia, Spain. 2013: Austria, France, 2012: Italy. 2 Estimates of people living with HIV are supplied by the country and not validated by UNAIDS: Austria, Belgium, Bulgaria, Canada, Denmark, France, Germany, Hungary, Iceland, Italy, Luxembourg, Malta, Netherlands, Portugal, Singapore, Spain, Switzerland, and the United Kingdom.

2 Estimates for citizens of the country only.
Figure 18: The London HIV treatment cascade among adults living with HIV, 2016

- 100% People living with HIV
- 90% People diagnosed with HIV
- 87% On treatment
- 85% Virally suppressed

Annual Epidemiological Spotlight on HIV in London: 2016 data
AMSTERDAM

FIGURE 3.11. HIV TESTING AND TREATMENT CASCADE, AMSTERDAM, 2015

HIV in the UK 2016 report

UK HIV continuum of care: progress against UNAIDS target
BOTSWANA HAS ACHIEVED THE 90–90–90 TARGETS

FIGURE 3.10. KNOWLEDGE OF HIV STATUS, ANTIRETROVIRAL THERAPY COVERAGE AND VIRAL SUPPRESSION AMONG PEOPLE LIVING WITH HIV, BOTSWANA, 2016

Source: UNAIDS special analysis, 2017; see annex on methods for more details.
ARE WE HIDING the truth

jennycupido.com
ON TRACK TO 30 MILLION PEOPLE ACCESSING TREATMENT

FIGURE 3.6. NUMBER OF PEOPLE LIVING WITH HIV ON ANTIRETROVIRAL THERAPY, GLOBAL, 2000–2016

- Number of people living with HIV on antiretroviral therapy
- 2020 target
The treatment target

HIV care cascade – WHO target

Diagnosed 90%  On treatment 90%  Virally suppressed 90%
Global results: HIV treatment cascade

- % of people living with HIV who know their HIV status: 57% (53-62%)
- % of people living with HIV who are on ART: 46% (43-50%)
- % of people living with HIV who are virally suppressed: 38% (35-41%)
Number of people newly infected with HIV

Source: UNAIDS/WHO estimates.
The red shading shows future targets.
Number of people dying from HIV

Source: UNAIDS/WHO estimates.
The red shading shows future targets.
KNOW YOUR HIV STATUS
HIV/AIDS AWARENESS IS EVERYONE'S BUSINESS

WE SUPPORT POZTO
HELPING THE TORONTO PEOPLE WITH AIDS FOUNDATION SINCE 2012

"Be aware that stigma and discrimination around HIV/AIDS continues to exist not only globally around the world, but on your own doorstep, too. So, stay informed and understand your human rights."

--Gwayne Bryk, Toronto

"Love yourself. Get informed and stay informed. Love others. Get connected and stay connected. You can transform the world with the truth."

--Nick Soulieris, Montreal
Hepatitis and HIV testing

- Aim of study was to identify rates of HIV testing in patients with HBV and/or HCV and to assess HIV testing practice in a large UK teaching hospital

- Retrospective case note review of 185 individuals with known hepatitis infection

• During the year preceding the diagnosis, 46.6% of the patients had sought medical advice owing to the presence of clinical indicators that should have led to HIV testing.\(^1\)

• Only 9% of patients eligible for screening were screened in an ED serving a population with a seroprevalence of 2%.\(^2\)

• Sixty-one percent reported not undergoing HIV testing after their last STI diagnosis.\(^3\)
HIV Stigma Scars
Heal the Pain. End the Shame.
HIV disclosure and stigma

Experiences in the dental setting compared to other clinical settings

- Staff not aware of HIV status
- Worried about being treated differently
- Reported being treated differently
- Felt refused or delayed treatment
- Avoided seeking care

- Dental practice
- GP practice
- GUM clinic

46% 40% 27% 15% 13% 5% 3% 5% 5% 2% 14% 14% 3%
WE'RE NOT IN 1984 ANYMORE, ANYMORE, ANYMORE, TO + O.

LEARN THE FACTS... HIV ISN'T WHAT IT USED TO BE.

THE STIGMA PROJECT
### Antiretrovirals available in 2018

<table>
<thead>
<tr>
<th>Category</th>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRTIs</td>
<td>Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zidovudine, TAF</td>
</tr>
<tr>
<td>NNRTIs</td>
<td>Delavirdine, Efavirenz, Etravirine, Nevirapine, Nevirapine XR, Rilpivirine</td>
</tr>
<tr>
<td>PIs</td>
<td>Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Tipranavir</td>
</tr>
<tr>
<td>NNRTIs</td>
<td>Delavirdine, Efavirenz, Etravirine, Nevirapine, Nevirapine XR, Rilpivirine</td>
</tr>
<tr>
<td>PIs</td>
<td>Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Tipranavir</td>
</tr>
<tr>
<td>Integrate Inhibitors</td>
<td>Raltegravir, Dolutegravir, Elvitegravir, Bictegravir</td>
</tr>
<tr>
<td>Fusion Inhibitors</td>
<td>Enfuvirtide</td>
</tr>
<tr>
<td>Fusion Inhibitors</td>
<td>Maraviroc</td>
</tr>
<tr>
<td>PK Boosters</td>
<td>Ritonavir, Cobicistat</td>
</tr>
<tr>
<td>Single Pill Regimens</td>
<td>Atripla, Eviplera, Stribild, Triumeq, Genvoya, Odefsey, Biktarvy</td>
</tr>
</tbody>
</table>

NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic

Adapted from [http://www.aidsmeds.com/list.shtml](http://www.aidsmeds.com/list.shtml)
ASCEND: HCV Treatment Efficacy and Adherence by Provider Type

• Nonrandomized phase IV trial of HCV-infected pts in Washington, DC (N = 600)
• Pts mostly male (69%), black (96%), GT1a (72%), and treatment naive (82%)
  – 20% of pts had compensated cirrhosis, 23% had HCV/HIV coinfection
• All providers received uniform 3-hr training
• No difference in SVR12 by provider type, cirrhosis status
• Adherence to all treatment visits by cirrhotic pts lower for specialists (61%) vs PCPs (56%) and NPs (75%) (P = .04)